Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).

出版年份 2017 全文链接

标题

作者

关键词

出版物

Volume 30, Issue 4_suppl, Pages 261-261

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-02-24

DOI

10.1200/jco.2012.30.4_suppl.261

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discuss science. Find collaborators. Network.

Join a conversation